Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REMPRO Registry A Multi-country, Multi-centre, Non-interventional, Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer

NCT04801186 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04801186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04801186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REMPRO Registry A Multi-country, Multi-centre, Non-interventional, Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
September 28, 2021
Completion date
September 30, 2022
Enrollment
1,920 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostates cancer